



ORIGINAL ARTICLE

Optimized Cytoplasmic Expression of Water Soluble Human Thrombopoietin in Modified Bacterial Strain

Mohammad Mouradi¹, Kamran Atarodi², Mahshid Mohammadipour¹, Kamran Mousavi Hosseini^{1*}

¹Department of Biotechnology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

²Department of Hematology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

ARTICLE INFO

Article History:

Received: 03.11.2018

Accepted: 06.01.2019

Keywords:

Thrombopoietin
Recombinant Protein
Escherichia coli
Blood Platelets

*Corresponding author:

Kamran Mousavi Hosseini,
Blood Transfusion Research Center,
High Institute for Research and
Education in Transfusion Medicine,
Tehran, Iran
Tel: +98 21 82052160
Email: mkmousavi@yahoo.com

ABSTRACT

Background: Thrombopoietin is a glycoprotein produced by liver and kidney which is responsible for regulating the platelet production. Thrombopoietin is a key ligand with impact on regulating the self-renewal of Hematopoietic stem cells and the regulation of Megakaryocytes progenitors. Previous studies have indicated that only N-terminal domain of this protein has receptor promoting ability. The goal of this study was to express the recombinant form of the soluble Thrombopoietin by using *Rosetta gami* strain of *Escherichia coli* as the expression host and pET vectors system to produce this cytokine in a cost-effective manner. **Methods:** After isolating the genomic sequence of Thrombopoietin from HepG2 cDNA, it was inserted into the pET32 vector and colonized by *DH5α*. Then, recombinant plasmids were transformed into *Rosetta gami* to express the recombinant protein. Expression was analyzed through SDS-PAGE and western blotting assays. Finally, the optimized time for induction and the suitable concentrations of IPTG were determined.

Results: DNA sequencing of recombinant plasmid proved that the sequence was indicative of variant 2 of Thrombopoietin. SDS-PAGE and western blotting showed a 36-kDa protein band which was compatible with the inserted sequence. Optimized time for expression was 6 h and optimized concentration of IPTG was 0.1 mM.

Conclusion: Although different methods are available to produce recombinant Thrombopoietin, low yield and costly setup are major obstacles in the production of Thrombopoietin. Also the products of usual bacterial systems are mostly inclusion bodies which is due to lacking disulfide bond formation. In this study, mutant strain of *E. coli* was used to provide a high level of water-soluble Thrombopoietin expression.

Please cite this article as: Mouradi M, Atarodi K, Mohammadipour M, Mousavi Hosseini K. Optimized Cytoplasmic Expression of Water Soluble Human Thrombopoietin in Modified Bacterial Strain. IJBC 2019; 11(1): 6-12.

Introduction

Thrombopoietin (TPO), also known as megakaryocyte growth and development factor (MDGF), is a cytokine that has attracted attention for its diverse roles on HSCs. This cytokine has the stimulating effect on megakaryocyte differentiation, and influences HSCs self-renewal through their proliferation phase. This cytokine is also important in maintaining the normal level of thrombopoiesis inside

of the body. Thrombopoietin is a glycoprotein consisting of 353 amino acids with a molecular weight of 30 kDa.¹

Human TPO gene is located on 3q27, between Chordin and RNA polymerase 2 genes.² Thrombopoietin gene consists of 6 exons and has 6 main splicing variants.³ Mature TPO contains two domains; each of them consisting 2 helix bundle.⁴ Its amino-terminal domain (174 amino acid) has receptor-binding and signaling

activity. While this domain of protein could support cellular proliferation,^{5,6} the carboxyl-terminal domain can enhance the secretion of protein into blood stream.

Main sources of TPO secretion in the human body are liver, kidney and bone marrow. TPO expression is regulated through a negative feedback in the body.^{7,8} C-mpl receptor is the main target of TPO. After binding of TPO, this receptor will dimerize,⁹ and Jak-2 will be phosphorylated, resulting in Jak-stat cascade signaling.¹⁰ Upon the receptor-ligand interaction, transcription of various transcription factors including SOCS, Bcl2, p27, HOX, and p21 will be upregulated. Each of these cytokines has their own specific influence on the HSCs.¹¹

The concentration of TPO inside of human blood is very low, and despite the other blood derived proteins that could be prepared by human plasma fractionation methods,¹²⁻¹⁴ this protein should be provided from other sources, mainly recombinant protein expression methods. Until now; a variety of expression methods have been used to express recombinant TPO, any of which having their own advantage and disadvantages.¹⁵

Previous studies have proven that glycosylation has a minus influence on the receptor binding ability of TPO to its receptor, but disulfide bond formation is critical to attaining tertiary structure which is necessary for receptor binding and its activation.⁹

Accordingly, using a host which is capable of forming disulfide bonds, but incapable of protein glycosylation would be appropriate to produce a functional protein.¹⁶

It's a concern to express soluble heterologous proteins in a bacterial host, because recombinant products of human proteins by usual bacterial system are in the inclusion body form due to inability of Disulfide bond formation.¹⁷ In this study, *Rosetta gami (DE3)* was used as a host to produce soluble TPO. *Rosetta gami* is a mutant strain of *E. coli* which enhances disulfide bond formation.¹⁸ This mutant strain has also been engineered to make it capable of recognizing human DNA codon usage. These adjustments resolve codon bias and post-translational modification related problems of the usual bacterial systems.^{19,20}

This study had 3 main phases including (I) gene isolation and cloning of the TPO functional domain, (II) TPO expression and (III) determining the optimized expression conditions to achieve a high yield of expression through a cost-effective method.

Materials and Methods

DNA polymerase enzymes were purchased from Thermofisher Corporation (U.S.A). Gel extraction, DNA purification, and plasmid purification kits were obtained from Qiagen Company (Germany). Ampicillin, chloramphenicol, and kanamycin were supplied from Sigma Aldrich Company (U.S.A), and size markers were purchased from Thermo scientific company (Lithuania).

Hep-G2 cell line was chosen as a source for TPO gene isolation. This cell line was cultured in DMEM-f12 media. Guanidinium thiocyanate-phenol-chloroform extraction method was performed to harvest total cell RNA. Hep-G2 RNA was used as a template in the synthesis of cDNA

through RT-PCR reaction.²¹

In order to isolate designated sequence, specific primers were designed for PCR reactions. TPO primers also had restriction sites embedded in their sequence (NcoI at forwarding primer and XhoI in reverse primer) which was located at their edges to make inserting the sequence in linear plasmid possible.

TPO-Forward primer:

CATGCCATGGTAAGCCCCGGCTCCTCCTGC

TPO-reverse primer:

CCGCTCGAGGAGCTCGTTCAGTGTGAGGAC

At this study, pET-32 was used as both cloning and expression vector. NcoI and XhoI are restriction sites were chosen because they could provide convenience in expression and purification of the target protein. Due to choosing these sites of restriction, the final product will be His-tag, S-tag and Trx-tag fusion proteins.²²⁻²⁴

For inserting the sequence of interest into the vector, pET32 plasmid and the PCR products were double digested with the same enzymes for 4 h at room temperature. Then, ligation performed by using T4 DNA ligase for 16 h at 40C.

As the cloning host, *DH5α* strain of *E. coli* was used. For making the competent bacterial cells for receiving the recombinant plasmid, the chemical competency method by cold CaCl₂ was carried out. For this purpose, 1.5ml of the fresh bacterial culture (600 nm OD=0.5) was centrifuged (8000g, at 40C) for 5 min. The provided sediment was suspended in 1ml of ice-cold CaCl₂ (0.1 M) and was placed on ice for 30 min. The suspension was centrifuged with the same condition of the previous step. After discharging the supernatant, 670 μL of the ice-cold CaCl₂ was added. Bacterial pellets were re-suspended in the mixture and placed on ice for another 30 min. At the end, the suspension was centrifuged again at the same condition and after discharging the supernatant, the pellet was re-suspended in 200 μL of ice-cold CaCl₂.

For transforming the ligation products into chemical competent *DH5α*, thermal shock was used. For this step, the ligation products were added to 100 μL of competent *DH5α* suspension and as a positive control, 1 μL of undigested vectors were used. The suspensions were placed on ice for 30 min, and after that placed on 42 oC bain-marie for 1 min. After one min, the suspensions immediately transferred on ice for two min.

After thermal shock, 1mL of LB media was added to the bacterial and suspension incubated at 37 oC for 45 min. Following this step, the suspensions centrifuged (2700g, 4 oC) for 10 min, and after discharging the extra supernatant, the pellets re-suspended in 200 μL of LB media and transferred on LB-agar plates. Ampicillin was used as a selection marker in the LB-agar to discriminate recombinant colonies from those that have not received the vector.

Recombinant colonies were subcultured and used as template for colony PCR assay. Recombinant plasmids were extracted from colonizing the host and further analyzed with PCR to make sure of recombinant plasmid. Recombinant plasmids were sequenced through the chain termination method by using universal T7 terminator

primer.²⁵

In order to express recombinant TPO, *Rosetta gami* (DE3) strain of *E. coli* was used.²⁶ This strain is resistant to chloramphenicol, tetracycline and kanamycin.²⁷ Chemical competency by using cold CaCl₂ and thermal shock (similar to the method used for *DH5α*) was applied to transfer recombinant plasmid into the expression host. For this stage, Ampicillin, Tetracycline, Chloramphenicol, and kanamycin were added to the medium for discriminating colonies of *Rosetta gami* with the recombinant vector. At this culturing condition, only those bacteria resistant to all these antibiotics could survive.

Since pET32 has lac operon (lac operator sequence),²⁸ Isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to induce expression of recombinant protein. For this step, bacterial colonies with recombinant plasmid were grown in Ampicillin, Tetracycline, Chloramphenicol, and kanamycin containing LB broth media. After 3 h of culturing, IPTG with the concentration of 1 M was used to induce the expression of recombinant TPO.²⁹

Upon 4 h of induction by IPTG, 2 samples, each 1 mL were taken from 2 different colonies and were sedimented. Tris-HCl buffer was added to the samples and sonication performed to lyse the bacteria. In order to prevent the action of bacterial proteases, mixture protease inhibitor was added to the sample and all the preparation steps performed on the ice.

To examine the expression of recombinant fusion TPO, the SDS-PAGE assay performed on the bacterial lysate. Electrophoresis assay performed with 12% SDS-PAGE gel, then samples further examined through western blotting. Monoclonal anti-His-tag antibodies were used for analyzing the expression of His-tag containing recombinant Thrombopoietin. These antibodies were conjugated with horseradish peroxidase (HRP) and 3,3'-diaminobenzidine (DAB) was used as a substrate for HRP.

In order to inspect the optimized time for large-scale production, 3 different samples were taken at 2, 4 and 6 h post induction. Another parameter that should have been determined was the optimized concentration of IPTG for inducing TPO expression.^{30,31} Different concentrations of IPTG ranging from 0.1 to 1 M were introduced into culture media and the production of recombinant protein was inspected.

Results

After amplification of TPO sequence through PCR reaction using Pfu enzyme and specific designed primers, the product was electrophoresed on agarose gel. Through this stage, a sharp and specific band between 500 and 600 base pairs was witnessed, compatible with the sequence of interest. The band was dissected and purified from agarose gel and used for further processing.

Cloning hosts of *E. coli* (*DH5α*) were transformed with ligation product of TPO sequence. Colony PCR assay showed that 2 colonies harbor the designated sequence (Figure 1).

Recombinant plasmids were sequenced and aligned with refseq-TPO sequence from gene bank (NCBI). The result




Figure 1: Colony PCR assay; 1- 100 bp DNA ladder, 2- Negative control, 3-Positive control (cDNA template), 4- Colony 1, 5- Colony 2




Figure 2: SDS-PAGE of bacterial lysate. 1- Protein size marker, 2-Colony 1 after 4 h of induction, 3-Colony 1 Non-induced after 4 h, 4-Colony 2 after 4 h of induction, 5- Colony 2 Non-induced after 4 h.

was identical to TPO splicing variant 2, consisting of 519 bp. After transforming recombinant vector into *Rosetta gami*, and induction by IPTG, protein expression was analyzed by SDS-PAGE analysis. It showed expression of a 36-kDa protein which is a fusion of TPO along with supportive tags (Figure 2).

The expressed proteins were further analyzed by western blot (Figure 3). Results indicated that only the recombinant protein bands had the capability to react with HRP conjugated anti-His-tag antibodies.

Appropriate induction time was investigated at 2, 4 and 6 h after induction (Figure 4). It was witnessed that 6 h after induction of protein expression has the highest level of TPO expression and could be considered as the optimized time for TPO production.

Optimized IPTG concentration for inducing TPO




Figure 3: Western blot analysis of Thrombopoietin expression (Semi-dry electro blotter). 1-Protein size marker, 2- Expression induced colony 1, 3-Expression induced colony 2.




Figure 4: SDS-PAGE electrophoresis of the recombinant TPO expression by Rosetta gami at different times upon induction. 1-Protein ladder, 2- Six h post induction, 3- four h post induction, 4-Two h post induction, 5- Before induction.




Figure 5: Determining optimized IPTG concentration for induction of recombinant TPO functional domain four h after induction. 1-Rosetta gami without the rec-plasmid, 2- Rosetta gami before induction, 3- Expression induction with 0.1 mM, 4- Induction with 0.2 mM, 5- Induction with 0.4 mM 6- Induction with 0.6 mM, 7- Induction with 0.8 mM, 8- Induction with 1 mM, 9-Protein ladder

expression was another parameter to be determined. It was investigated at 0.1 to 1 Mm concentration (Figure 5). The visual evaluation showed that 0.1 mM of IPTG concentration provides satisfying levels of protein expression.

Discussion

Thrombopoietin is a cytokine that has attracted attention due to its diverse roles on HSCs.⁶ This cytokine has stimulating effect on megakaryocyte differentiation,³² and poses a critical influence on self-renewal of HSCs.³³ Since a complete understanding of Thrombopoietin and different aspects of its influence is calling for further studies, it's quite an issue to have a satisfactory resource of this cytokine.

Due to its scarce amount in human plasma, it's almost impossible to harvest Thrombopoietin through blood fractionation methods,³⁴⁻³⁶ which leaves no alternative except using biotechnological methods to produce

recombinant TPO. So far, lots of attempts have been made on cloning and expression of this cytokine, but they mostly suffer from downsides which result in increased costs of recombinant TPO. An optimized expression method to produce water soluble recombinant protein in a cost effective manner is an important issue.

Previously many attempts have been dedicated for producing recombinant TPO and different expression systems have been used including both prokaryotic and eukaryotic ones. Desired expression systems are those which could have the highest yield of production while they could be considered as cost effective.

In a study by Hou et al. the *E. coli* expression system was used for recombinant production of TPO-153. At that study it was reported that the genomic sequence of TPO was synthesized according to the human codon usage. Also the expression product of TPO-153 were inclusion bodies which required further processing to achieve active form of the protein.³⁷

Apart from the bacterial codon bias, one major problem using unmodified *E. coli* expression host systems is lack of capability for disulfide bonding formation.³⁸ These bacteria usually express recombinant proteins in the form of inclusion bodies, which causes a budget burden.

In another study, Foster et al. isolated the human TPO gene from fibroblast DNA genomic library and inserted the sequence of TPO into pZGTPO-124 vector. By using LipofectAMINE, they transfected the Hamster BHK 570 cells and isolated the stable TPO producing cell lines with methotrexate. The final products were biologically active.³⁹ In 2000, Kaszubska W, et al. used Chinese hamster ovary (CHO) cells for expression of full length TPO. In their study, the final products were having the glycosylation sites and were biologically active.⁴⁰

The studies that were using eukaryotic host did not require the synthesizing of optimized sequence, but it should be kept in mind that bacterial hosts provide a higher yield of expression compared with the eukaryotic ones. It is worthy to mention that full length expression could reduce the overall yield of expression by the bacteria. On the other side, as it was mentioned earlier, the glycosylation and full length expression are not necessary for the activation of the C-mpl receptor.

Guo et al. reported using pET32a (+)/TPO for expression of recombinant TPO. In their study, the *Origami (DE3)* which is an engineered strain of *E. coli*, was used for expression of recombinant TPO. This strain is capable of producing disulfide bonds, but cannot recognize human codon usage and for that the sequence of interest needs to be synthesized. It was shown by their study that the expression system was effective for producing the recombinant TPO and the final recombinant products were constituting more than 40 percent of the total protein produced by the host cells.⁴¹

In the current study, the Hep G2 cell line cDNA was used to isolate TPO sequence. In comparison with previous prokaryotic studies, in the current study the requirement for synthesizing optimized sequence of TPO was bypassed, because the *Rosetta gami* strain could realize the human codon usage. Also the final products were expressed in the water soluble form that could reduce the cost of protein production.

SDS-PAGE and western blotting by His-tag monoclonal antibody confirmed that specified sequence has been expressed by the bacterial host. Inserting His-tag sequence was performed to ease protein purification by Ni-column.⁴² This adjustment also was helpful in detection protein by western blotting.

Conclusion

Expressing recombinant human Thrombopoietin by using bacterial systems is an important issue. A still remaining concern for production of this recombinant protein by such a system is its inability to form disulfide bonds on the grounds of the oxide cytoplasm condition of bacteria which renders the final products as inclusion bodies. The new approach of using modified bacterial hosts is preferable for producing recombinant proteins like TPO that do not necessarily need glycosylation sites.

Adopting both *Rosetta gami* as a host and pET32 as a vector resulted in a high production of the recombinant soluble TPO in the cytoplasm of the bacteria.

Acknowledgement

This article is the result of a thesis in Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine. We wish to thank the Institute for the financial and moral support.

Conflict of Interest: None declared.

References

1. Feese MD, Tamada T, Kato Y, Maeda Y, Hirose M, Matsukura Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. *Proc Natl Acad Sci U S A*. 2004; 101(7): 1816-21. doi:10.1073/pnas.0308530100. PubMed PMID:14769915. PubMed Central PMCID:357010.
2. von dem Borne AEK, Folman C, Linthorst GE, Porcelijn L, van den Oudenrijn S, van der Schoot E, et al. 10 Thrombopoietin and its receptor: structure, function and role in the regulation of platelet production. *Baillière's clinical haematology*. 1998; 11(2): 409-26.
3. Millot GA, Feger F, Garçon L, Vainchenker W, Dumenil D, Svinarchuk F. MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth. *Experimental hematology*. 2002; 30(2): 166-75.
4. Miyakawa Y, Drachman JG, Gallis B, Kaushansky A, Kaushansky K. A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl. *J Biol Chem*. 2000; 275(41): 32214-9. doi:10.1074/jbc.M005080200. PubMed PMID:10918061.
5. Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. *Blood*. 1995; 85(4): 981-8. PubMed PMID:7849319.
6. Marcucci R, Romano M. Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond. *Biochim Biophys Acta*. 2008; 1782(7-8): 427-32. doi:10.1016/j.bbdis.2008.03.007. PubMed PMID:18433726.
7. Khaspekova SG, Shustova ON, Golubeva NV, Vasiliev SA, Mazurov AV. Relationships of mean platelet volume and plasma thrombopoietin with glycofalin levels in thrombocytopenic patients. *Acta Haematol*. 2015; 133(3): 295-9. doi:10.1159/000362531. PubMed PMID:25472766.
8. Asanuma M, Seino K, Mizuno T, Nasu M, Yamauchi F, Fujishima M. Plasma thrombopoietin level and platelet indices in hemodialysis patients receiving recombinant human erythropoietin. *Int J Lab Hematol*. 2010; 32(3): 312-9. doi:10.1111/j.1751-

- 553X.2009.01191.x. PubMed PMID:19878361.
9. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell*. 2007; 1(6): 685-97. doi:10.1016/j.stem.2007.10.020. PubMed PMID:18371409.
 10. Kohlscheen S, Wintterle S, Schwarzer A, Kamp C, Brugman MH, Breuer DC, et al. Inhibition of Thrombopoietin/Mpl Signaling in Adult Hematopoiesis Identifies New Candidates for Hematopoietic Stem Cell Maintenance. *PLoS One*. 2015; 10(7): e0131866. doi:10.1371/journal.pone.0131866. PubMed PMID:26147434. PubMed Central PMCID:4493002.
 11. Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, et al. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. *Ann Hematol*. 2015; 94(1): 117-28. doi:10.1007/s00277-014-2158-1. PubMed PMID:25069650.
 12. Mousavi Hosseini K, Nasiri S, Heidari M. Separation of albumin from the human plasma by ethanol and low temperature. *Journal of Zanjan University of Medical Sciences and Health Services*. 2013;21(85):74-84.
 13. Hosseini KM, Dinarvand R, Pourmokhtar M, Rezvan H, Jalil MA. Pasteurization of IgM-enriched immunoglobulin. *DARU Journal of Pharmaceutical Sciences*. 2004; 12(1): 40-3.
 14. Shooshtari MM, Hosseini KM. Evaluation of the plasma quality after filtration. *Daru: journal of Faculty of Pharmacy, Tehran University of Medical Sciences*. 2010; 18(2): 114.
 15. Sung YH, Lee GM. Enhanced human thrombopoietin production by sodium butyrate addition to serum-free suspension culture of bcl-2-overexpressing CHO cells. *Biotechnol Prog*. 2005; 21(1): 50-7. doi:10.1021/bp049892n. PubMed PMID:15903240.
 16. Akkerman JWN. Thrombopoietin and platelet function. *Seminars in thrombosis and hemostasis*; 2006: Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ...; 2006. p. 295-304.
 17. Eggenreich B, Willim M, Wurm DJ, Herwig C, Spadiut O. Production strategies for active heme-containing peroxidases from *E. coli* inclusion bodies—a review. *Biotechnology Reports*. 2016; 10(75-83).
 18. Yedahalli SS, Rehmann L, Bassi A. Expression of exo-inulinase gene from *Aspergillus niger* 12 in *E. coli* strain Rosetta-gami B (DE3) and its characterization. *Biotechnology progress*. 2016; 32(3): 629-37.
 19. Rudolf S, Lipowsky R. Protein Synthesis in *E. coli*: Dependence of Codon-Specific Elongation on tRNA Concentration and Codon Usage. *PLoS One*. 2015; 10(8): e0134994. doi:10.1371/journal.pone.0134994. PubMed PMID:26270805. PubMed Central PMCID:4535986.
 20. Duquesne S, Destoumieux-Garzón D, Zirah S, Knappe TA, Goulard C, Peduzzi J, et al. Post-translational modification and folding of a lasso-type gene-encoded antimicrobial peptide require two enzymes only in *Escherichia coli*. *Peptides for Youth*: Springer; 2009: 35-6.
 21. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. *Biotechniques*. 1999; 26(1): 112-22, 24-5. doi:10.2144/99261rv01. PubMed PMID:9894600.
 22. Liu ZQ, Yang PC. Construction of pET-32 alpha (+) Vector for Protein Expression and Purification. *N Am J Med Sci*. 2012; 4(12): 651-5. doi:10.4103/1947-2714.104318. PubMed PMID:23272309. PubMed Central PMCID:3530323.
 23. Loughran ST, Loughran NB, Ryan BJ, D'Souza BN, Walls D. Modified His-tag fusion vector for enhanced protein purification by immobilized metal affinity chromatography. *Anal Biochem*. 2006; 355(1): 148-50. doi:10.1016/j.ab.2006.05.011. PubMed PMID:16814244.
 24. Corsini L, Hothorn M, Scheffzek K, Sattler M, Stier G. Thioredoxin as a fusion tag for carrier-driven crystallization. *Protein Science*. 2008; 17(12): 2070-9.
 25. Buckley RM, Stubbe J. Chemistry with an artificial primer of polyhydroxybutyrate synthase suggests a mechanism for chain termination. *Biochemistry*. 2015; 54(12): 2117-25. doi:10.1021/bi501405b. PubMed PMID:25741756. PubMed Central PMCID:4684083.
 26. Fathi-Roudsari M, Akhavian-Tehrani A, Maghsoudi N. Comparison of Three *Escherichia coli* Strains in Recombinant Production of Reteplase. *Avicenna J Med Biotechnol*. 2016; 8(1): 16-22. PubMed PMID:26855731. PubMed Central PMCID:4717461.
 27. Kong B, Guo GL. Soluble expression of disulfide bond containing proteins FGF15 and FGF19 in the cytoplasm of *Escherichia coli*. *PLoS One*. 2014; 9(1): e85890. doi:10.1371/journal.pone.0085890. PubMed PMID:24465767. PubMed Central PMCID:3896424.
 28. Pan SH, Malcolm BA. Reduced background expression and improved plasmid stability with pET vectors in BL21 (DE3). *Biotechniques*. 2000; 29(6): 1234-8. doi:10.2144/00296st03. PubMed PMID:11126126.
 29. Munro PD, Ackers GK, Shearwin KE. Aspects of protein-DNA interactions: a review of quantitative thermodynamic theory for modelling synthetic circuits utilising LacI and CI repressors, IPTG and the reporter gene lacZ. *Biophysical reviews*. 2016; 8(4): 331-45.
 30. Larentis AL, Nicolau JFMQ, dos Santos Esteves G, Vareschini DT, de Almeida FVR, dos Reis MG, et al. Evaluation of pre-induction temperature, cell growth at induction and IPTG concentration on the

- expression of a leptospiral protein in *E. coli* using shaking flasks and microbioreactor. *BMC research notes*. 2014; 7(1): 671.
31. Einsfeldt K, Severo Junior JB, Correa Argondizzo AP, Medeiros MA, Alves TL, Almeida RV, et al. Cloning and expression of protease ClpP from *Streptococcus pneumoniae* in *Escherichia coli*: study of the influence of kanamycin and IPTG concentration on cell growth, recombinant protein production and plasmid stability. *Vaccine*. 2011; 29(41): 7136-43. doi:10.1016/j.vaccine.2011.05.073. PubMed PMID:21651937.
 32. Pang SF, Li XK, Zhang Q, Yang F, Xu P. Interference RNA (RNAi)-based silencing of endogenous thrombopoietin receptor (Mpl) in Dami cells resulted in decreased hNUDC-mediated megakaryocyte proliferation and differentiation. *Exp Cell Res*. 2009; 315(20): 3563-73. doi:10.1016/j.yexcr.2009.06.020. PubMed PMID:19560457.
 33. de Graaf CA, Metcalf D. Thrombopoietin and hematopoietic stem cells. *Cell Cycle*. 2011; 10(10): 1582-9. doi:10.4161/cc.10.10.15619. PubMed PMID:21478671. PubMed Central PMCID:3127159.
 34. Mousavi Hosseini K, Rezvan H, Motalleb Z, Chabokpey S, Mirbod V. Study of the heat-treated human albumin stabilization by caprylate and acetyltryptophanate. *Iranian Biomedical Journal*. 2002; 6(4): 135-40.
 35. Mousavi Hosseini K, Heidari M, Yari F. The preparation of albumin as a biological drug from human plasma by filtration. *Tehran University Medical Journal*. 2011; 69(5):283-288.
 36. Mousavi HK. Preparation of plasminogen by affinity chromatography. 2014.
 37. Hou J, Zhan H. Expression of active thrombopoietin and identification of its key residues responsible for receptor binding. *Cytokine*. 1998; 10(5): 319-30. doi:10.1006/cyto.1997.0299. PubMed PMID:9619369.
 38. Ke N, Berkmen M. Production of Disulfide-Bonded Proteins in *Escherichia coli*. *Curr Protoc Mol Biol*. 2014; 108(1): 16 1B 1-21. doi:10.1002/0471142727.mb1601bs108. PubMed PMID:25271713.
 39. Foster DC, Sprecher CA, Grant FJ, Kramer JM, Kuijper JL, Holly RD, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. *Proc Natl Acad Sci U S A*. 1994; 91(26): 13023-7. PubMed PMID:7809166. PubMed Central PMCID:45573.
 40. Kaszubska W, Zhang H, Patterson RL, Suhar TS, Uchic ME, Dickinson RW, et al. Expression, purification, and characterization of human recombinant thrombopoietin in Chinese hamster ovary cells. *Protein Expr Purif*. 2000; 18(2): 213-20. doi:10.1006/prep.1999.1190. PubMed PMID:10686152.
 41. Guo SQ, Xi YZ, Yuan ZH, Cui JW, Liang F. [Fusion construction, prokaryotic expression and structure characteristics prediction of bimolecular thrombopoietin]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2004; 20(4): 380-4. PubMed PMID:21158121.
 42. Imani M, Jaliani HZ, Kheirandish MH, Azadpour M. Recombinant production and affinity purification of the FraC pore forming toxin using hexa-His tag and pET expression cassette. *Iranian journal of basic medical sciences*. 2017; 20(4): 380.